Amyl therapeutics is a preclinical-stage biotechnology company pioneering a breakthrough approach to treating severe peripheral amyloid protein misfolding diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a transformative impact on the lives of patients affected by neurodegenerative diseases such as Alzheimer's and Parkinson's diseases, or by systemic amyloidosis. 

Our approach is shaped by an experienced team with deep drug development experience, and productive collaborations with world-class advisors and partners.

Amyl Therapeutics

Org chart

Teams

Offices